12:00 AM
Dec 19, 2011
 |  BC Week In Review  |  Company News  |  Deals

Reata, Abbott deal

Reata partnered with Abbott to co-develop and co-commercialize Reata's portfolio of second-generation antioxidant inflammation modulators (AIMs) worldwide. The portfolio includes compounds in preclinical development for pulmonary, CNS and immunology indications. Reata will receive $400 million up front....

Read the full 164 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >